KRAS and non-small cell lung carcinoma: In a Phase II study (ClinicalTrials.gov Identifier: NCT01778803) (75) on defactinib (VS-6063; a selective oral inhibitor of FAK) treatment of advanced KRAS-mutant NSCLC, defactinib monotherapy showed moderate clinical activity.